Skip to main content
. 2022 Apr 29;14(9):1879. doi: 10.3390/nu14091879

Figure 4.

Figure 4

Plasma levels of triglycerides (TG) significantly decreased following SAx treatment (oral supplementation with hydroxytyrosol (HT) and punicalagin (PC)) (black color) in subjects with hypertriglyceridemia, a risk factor for CVD, (n = 4) (* p < 0.05). This effect was not observed after placebo treatment (gray color). The data repreScheme.